Protara Therapeutics (TARA) Change in Acquisitions & Divestments (2014 - 2026)

Protara Therapeutics (TARA) has reported Change in Acquisitions & Divestments for 11 consecutive years, with $29.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 288.48% year-over-year to $29.1 million; the TTM figure through Mar 2026 stood at $86.9 million (up 163.24% YoY), while the FY2025 annual figure was $65.2 million, up 34.23% from the prior year.
• Change in Acquisitions & Divestments declined to $29.1 million in Q1 2026 per TARA's latest filing, from $35.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $35.8 million in Q4 2025 and bottomed at $3.0 million in Q2 2024.
• Historically, Change in Acquisitions & Divestments has averaged $17.0 million across 5 years, with a median of $18.5 million in 2022.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments sank 86.58% — and 2026, when it surged 288.48%.
• Protara Therapeutics' Change in Acquisitions & Divestments stood at $10.8 million in 2022, then jumped by 34.64% to $14.5 million in 2023, then jumped by 54.98% to $22.5 million in 2024, then surged by 59.22% to $35.8 million in 2025, then decreased by 18.67% to $29.1 million in 2026.
• Business Quant data shows TARA's Change in Acquisitions & Divestments at $29.1 million in Q1 2026, $35.8 million in Q4 2025, and $17.9 million in Q3 2025.